top of page
Our Pipeline
Advancing Innovative Therapies for a Healthier Tomorrow
SV-101 is a novel antisense oligonucleotide being developed for the treatment of peripheral sensorineural olfactory loss. Preclinical data in mice and non human primates demonstrate promising efficacy and a favorable safety profile.
Olfactory Loss
Lead Candidate: SV-101
Olfactory Loss
Lead Candidate: SV-101
SV-101 is a novel antisense oligonucleotide being developed for the treatment of peripheral sensorineural olfactory loss. Preclinical data in mice and non human primates demonstrate promising efficacy and a favorable safety profile.
SV-101 is a novel antisense oligonucleotide being developed for the treatment of peripheral sensorineural olfactory loss. Preclinical data in mice and non human primates demonstrate promising efficacy and a favorable safety profile.
bottom of page